

- 119]. 37th Annual meeting of the New Clinical Drug Evaluation Unit (NCDEU) program: 1997 May 27-30; Boca Raton
65. Lydiard RB, Loraia MT, Ballenger JC, et al. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. *Am J Psychiatry* 1987; 144: 664-5
66. Marks J. The benzodiazepines. Lancaster: MTP Press Limited, 1985: 100-5
67. Lecrubier Y, Bourin M, Moon CAL, et al. Efficacy of venlafaxine in depressive illness in general practice. *Acta Psychiatr Scand* 1997; 95: 485-93
68. Khan A, Upton V, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. *J Clin Psychopharmacol* 1998; 18: 19-25
69. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. *J Affect Disord* 1998; 47: 55-62

Correspondence and reprints: Dr David Bakish, Psychopharmacology Unit, Royal Ottawa Hospital, 1145 Carling Avenue, Ottawa, Ontario, K1G 7K4, Canada.
E-mail: dbakish@rohcg.on.ca

Errata

Vol.7, No. 4, page 340: Reference 64 should read: 'LeWitt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. *Neurology* 1983 Aug; 33: 1009-14'

[Markham A, Benfield P. Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease. *CNS Drugs* 1997 Apr; 7 (4): 328-40]

Vol.8, No.2, page 155: In column 1, line 9 should read: '...15 mg/day...'

[Davis R, Markham A. Ziprasidone. *CNS Drugs* 1997; 8 (2): 153-9]

Vol.9, No. 2, page 153: In the list of reviewers of the manuscript, the following name should be added: **W. Fleischacker**, Department of Psychiatry, University of Innsbruck, Innsbruck, Austria

[Prakash A, Lamb HM. Zotepine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. *CNS Drugs* 1998; 9 (2): 153-75]